Clinical Trial Record

Return to Clinical Trials

Anatomical-Clinical Base of Adenocarcinoma Pancreatic


2023-11-16


2035-01-31


2035-02-28


1500

Study Overview

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice. The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy). The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on: * the development of new diagnostic tools, * understanding the development of tumors of the pancreas * the development of new therapeutic targets * understanding the response to chemotherapy…

  • Adenocarcinoma
  • Carcinoma
  • Neoplasms
  • OTHER: collection of biological samples
  • RC31/21/0191
  • 2021-A01050-41 (OTHER Identifier) (OTHER: ID-RCB)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2023-11-07  

N/A  

2025-01-29  

2023-11-07  

N/A  

2025-02-03  

2023-11-13  

N/A  

2025-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
Primary Outcome MeasuresMeasure DescriptionTime Frame
Enrichment of prospective BACAP collectionThis collection is coming to enrich the prospective BACAP collection of fresh tumor tissue and/or fixed from the micro-biopsy under endoscopic ultrasound5 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Barbara BOURNET, MD, PhD

Phone Number: (0)5 61 32 32 35

Email: bournet.b@chu-toulouse.fr

Study Contact Backup

Name: Cindy CANIVET, PhD

Phone Number: (0)5 61 32 20 48

Email: canivet.c@chu-toulouse.fr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
  • Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
  • Patient with pancreatic adenocarcinoma proven histologically and/or cytologically

  • Exclusion Criteria:

  • Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
  • Pregnant or breastfeeding patient

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Barbara BOURNET, MD, PhD, University Hospital, Toulouse

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    • Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabieres C. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project. BMC Cancer. 2024 Jun 10;24(1):709. doi: 10.1186/s12885-024-12463-8.